Publication details

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial

Authors

MAURER Marcus STOBIECKI Marcin VALERIEVA Anna HAKL Roman STAEVSKA Maria T BOUILLET Laurence DU-THANH Aurélie KESSEL Aharon KIANI-ALIKHAN Sorena MAGERL Markus RESHEF Avner BAEZA Maria Luisa FAIN Olivier FARKAS Henriette GREVE Jens GUILARTE Mar JACOBS Joshua S LI H Henry LLEONART Ramon MANNING Michael E SUSSMAN Gordon L ANDERSON John CHAPDELAINE Hugo COHN Danny M HAGIN David KRÁLÍČKOVÁ Pavlína RITCHIE Bruce SPADARO Giuseppe STAUBACH Petra TARZI Michael D YANG William H MARIE-HELENE Jouvin CRABBÉ Rafael LEEUWEN Simone van CHEN Huaihou ZHU Li KNOLLE Jochen LESAGE Anne LU Peng RIEDL Marc A AYGÖREN-PÜRSÜN Emel

Year of publication 2026
Type Peer-reviewed scientific article
Magazine / Source Lancet Haematolgy
MU Faculty or unit

Faculty of Medicine

Citation
web https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext
Doi https://doi.org/10.1016/S2352-3026(25)00341-2
Description Hereditary angioedema is a bradykinin-mediated disorder characterised by recurrent painful swelling attacks. Treatment relies on medications to prevent attacks and on-demand therapies for attack manifestations. Parenteral administration associated with most available on-demand therapies often leads to treatment being delayed or forgone. Deucrictibant is an orally bioavailable bradykinin B2 receptor antagonist under development for prophylaxis and on-demand treatment of hereditary angioedema attacks. We aimed to investigate the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema attacks.

You are running an old browser version. We recommend updating your browser to its latest version.

More info